Invest New Drugs 2017 – Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J., . . . Schneller, F., III. (2017, March 1). A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. Retrieved March 24, 2017, from Springedink.com.

This article is about a Phase II study that was conducted with Beta 1,3-1,6 Glucan being used in conjunction with anti-tumor antibody therapies. Lung Cancer is the third most frequent type of Cancer, after Breast and Prostate Cancers. NSCLC, non-small cell lung cancer, makes up 85% of lung cancers. Traditionally it has been treated with chemotherapies. With increased research, Monoclonal Antibodies are now being used with a great deal of success. The combination therapy with BTH1677 (Beta Glucan; Imprine PGG) and cetuximab, was well tolerated by patients. Cetuximab was later not approved for advanced stages of NSCLC, but the combination has been successful with other Monoclonal antibodies.  Read more…